BioLine Rx (FRA:YP2) Tariff Resilience Score: 3/10 (As of Jul. 03, 2026)


FRA:YP2 BioLine Rx Ltd FRA:YP2
21 GF Score
Price €2.54
! 5 Warning Signs
View Full Analysis

What is BioLine Rx Tariff Resilience Score?

BioLine Rx FRA:YP2 +3.25% 21 Tariff Resilience Score is 3 as of Jul. 03, 2026. GuruFocus rates FRA:YP2 with a GF Score™ of 21/100. The stock has 5 warning signs investors should review. Among 1,373 Biotechnology companies, BioLine Rx ranks worse than 50.69% on this metric.

BioLine Rx has the Tariff Resilience Score of 3, which implies that the company might have .

BioLine Rx has Significant reliance on international pharmaceutical supply chains. Vulnerable to tariff changes due to limited alternative suppliers and high import/export balance. Historical impacts have been notable.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes BioLine Rx might have .

BioLine Rx  (FRA:YP2) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

BioLine Rx Tariff Resilience Score Related Terms

FRA:YP2 vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, BioLine Rx's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Tariff Resilience Score falls into.


FRA:YP2
21GF Score
BioLine Rx Ltd FRA:YP2
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 3 mean?
BioLine Rx (FRA:YP2) has a Tariff Resilience Score of 3 as of Jul. 03, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, BioLine Rx ranks #696 out of 1373 companies in the Biotechnology industry, placing it in the top 50.7%.
Is BioLine Rx's Tariff Resilience Score too high?
BioLine Rx's current Tariff Resilience Score is 3. The Biotechnology industry median Tariff Resilience Score is 4.00. BioLine Rx's value of 3 is 25% below this industry median. Based on the distribution chart, BioLine Rx ranks #696 out of 1373 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioLine Rx has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does BioLine Rx's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioLine Rx ranks #696 out of 1373 companies for Tariff Resilience Score. This places BioLine Rx in the lower half of its industry. The industry median Tariff Resilience Score is 4.00. BioLine Rx's value of 3 is 25% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLine Rx's current Tariff Resilience Score of 3 is 25% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLine Rx's current Tariff Resilience Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLine Rx stock overvalued right now?
BioLine Rx (FRA:YP2) has a current Tariff Resilience Score of 3. The current Tariff Resilience Score is 3 and 25% below the Biotechnology industry median of 4.00. BioLine Rx's overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For BioLine Rx (FRA:YP2), the current Tariff Resilience Score is 3 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioLine Rx Business Description

Other Exchanges BLRX:USABLRX:Israel
Address 2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
21GF Score

Get the complete analysis for FRA:YP2

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.54
Price